Literature DB >> 21996099

Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication.

Suresh Pallikkuth1, Kenneth Rogers, Francois Villinger, Melvin Dosterii, Monica Vaccari, Genoveffa Franchini, Rajendra Pahwa, Savita Pahwa.   

Abstract

We have previously shown that interleukin-21, a pleiotropic C γ-chain signaling cytokine, induces the expression of the cytotoxic molecules granzyme B (GrB) and perforin in vitro in CD8 T cells and NK cells of chronically HIV infected individuals. In this pilot study, four chronically SIV infected rhesus macaques (RM) in late-stage disease were given two doses of recombinant MamuIL-21, 50 μg/kg, intravenously 7 days apart, followed by one subcutaneous dose, 100 μg/kg, 23 days after the second dose. Three animals served as controls. After each dose of IL-21, increases were noted in frequency and mean fluorescence intensity of GrB and perforin expression in memory and effector subsets of CD8 T cells in peripheral blood (PB), in peripheral and mesenteric lymph node (LN) cells, in PB memory and effector CD4 T cells and in NK cells. Frequencies of SIV-gag specific CD107a(+)IFN-γ(+) CD8 T cells increased 3.8-fold in PB and 1.8-fold in LN. In addition, PB CD27(+) memory B cells were 2-fold higher and serum SIV antibodies increased significantly after IL-21 administration. No changes were observed in markers of T cell activation, T cell proliferation or plasma virus load. Thus, administration of IL-21 to chronically SIV infected viremic animals was safe, well tolerated and could augment the cytotoxic potential of T cells and NK cells, promote B cell differentiation with increases in SIV antibody titers without discernable increase in cellular activation. Further studies are warranted to elucidate the effects and potential benefit of IL-21 administration in the context of SIV/HIV infection and in SIV/HIV vaccine design. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996099      PMCID: PMC3260006          DOI: 10.1016/j.vaccine.2011.09.118

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  68 in total

1.  Skewed maturation of memory HIV-specific CD8 T lymphocytes.

Authors:  P Champagne; G S Ogg; A S King; C Knabenhans; K Ellefsen; M Nobile; V Appay; G P Rizzardi; S Fleury; M Lipp; R Förster; S Rowland-Jones; R P Sékaly; A J McMichael; G Pantaleo
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

2.  Natural killer cells that respond to human immunodeficiency virus type 1 (HIV‐1) peptides are associated with control of HIV‐1 infection.

Authors:  Caroline T Tiemessen; Sharon Shalekoff; Stephen Meddows-Taylor; Diana B Schramm; Maria A Papathanasopoulos; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

3.  Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells.

Authors:  Anita Parmigiani; Maria F Pallin; Helena Schmidtmayerova; Mathias G Lichtenheld; Savita Pahwa
Journal:  Hum Immunol       Date:  2010-10-25       Impact factor: 2.850

4.  HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function.

Authors:  Mathieu F Chevalier; Boris Jülg; Augustine Pyo; Michael Flanders; Srinika Ranasinghe; Damien Z Soghoian; Douglas S Kwon; Jenna Rychert; Jeffrey Lian; Matthias I Muller; Sam Cutler; Elizabeth McAndrew; Heiko Jessen; Florencia Pereyra; Eric S Rosenberg; Marcus Altfeld; Bruce D Walker; Hendrik Streeck
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

5.  In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS.

Authors:  F Villinger; S Bucur; N F Chikkala; S S Brar; P Bostik; A E Mayne; J Adams; M E Lee; F J Novembre; M K Gately; A A Ansari; C D Hillyer
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

6.  An IL-2/Ig fusion protein influences CD4+ T lymphocytes in naive and simian immunodeficiency virus-infected Rhesus monkeys.

Authors:  A Craiu; D H Barouch; X X Zheng; M J Kuroda; J E Schmitz; M A Lifton; T D Steenbeke; C E Nickerson; K Beaudry; J D Frost; K A Reimann; T B Strom; N L Letvin
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-01       Impact factor: 2.205

7.  Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques.

Authors:  A A Ansari; A E Mayne; J B Sundstrom; P Bostik; B Grimm; J D Altman; F Villinger
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers.

Authors:  LaTonya D Williams; Anju Bansal; Steffanie Sabbaj; Sonya L Heath; Wei Song; Jianming Tang; Allan J Zajac; Paul A Goepfert
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

9.  Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.

Authors:  J Parrish-Novak; S R Dillon; A Nelson; A Hammond; C Sprecher; J A Gross; J Johnston; K Madden; W Xu; J West; S Schrader; S Burkhead; M Heipel; C Brandt; J L Kuijper; J Kramer; D Conklin; S R Presnell; J Berry; F Shiota; S Bort; K Hambly; S Mudri; C Clegg; M Moore; F J Grant; C Lofton-Day; T Gilbert; F Rayond; A Ching; L Yao; D Smith; P Webster; T Whitmore; M Maurer; K Kaushansky; R D Holly; D Foster
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

10.  Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.

Authors:  Z Hel; D Venzon; M Poudyal; W P Tsai; L Giuliani; R Woodward; C Chougnet; G Shearer; J D Altman; D Watkins; N Bischofberger; A Abimiku; P Markham; J Tartaglia; G Franchini
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

View more
  38 in total

Review 1.  Interleukin-21: a double-edged sword with therapeutic potential.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

Review 2.  Attacking the HIV reservoir from the immune and viral perspective.

Authors:  Marta Massanella; Javier Martinez-Picado; Julià Blanco
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

Review 3.  Expansion or depletion of T follicular helper cells during HIV infection: consequences for B cell responses.

Authors:  Olusegun O Onabajo; Joseph J Mattapallil
Journal:  Curr HIV Res       Date:  2013-12       Impact factor: 1.581

4.  IL-21 Therapy Controls Immune Activation and Maintains Antiviral CD8+ T Cell Responses in Acute Simian Immunodeficiency Virus Infection.

Authors:  Gema Méndez-Lagares; Ding Lu; David Merriam; Christopher A Baker; François Villinger; Koen K A Van Rompay; Joseph M McCune; Dennis J Hartigan-O'Connor
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11       Impact factor: 2.205

Review 5.  T cell exhaustion during persistent viral infections.

Authors:  Shannon M Kahan; E John Wherry; Allan J Zajac
Journal:  Virology       Date:  2015-01-22       Impact factor: 3.616

6.  Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Thorsten Demberg; Ranajit Pal; Marjorie Robert-Guroff
Journal:  Immunology       Date:  2015-06       Impact factor: 7.397

Review 7.  Immunosenescence and hurdles in the clinical management of older HIV-patients.

Authors:  Marco Ripa; Stefania Chiappetta; Giuseppe Tambussi
Journal:  Virulence       Date:  2017-02-21       Impact factor: 5.882

Review 8.  Innate and Adaptive Immune Regulation During Chronic Viral Infections.

Authors:  Elina I Zuniga; Monica Macal; Gavin M Lewis; James A Harker
Journal:  Annu Rev Virol       Date:  2015-09-02       Impact factor: 10.431

Review 9.  Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines.

Authors:  Morgan A Reuter; Carolina Pombo; Michael R Betts
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

Review 10.  Anti-viral CD8 T cells and the cytokines that they love.

Authors:  Maureen A Cox; Shannon M Kahan; Allan J Zajac
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.